ArticleACR open rheumatology2020
Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement.
Article in ACR open rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Intracranial GCA: a comprehensive systematic review.Rheumatology (Oxford, England) · 2025Pooled it
- Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.Arthritis research & therapy · 2023Pooled it
- A corona-like distribution and patchy pattern of cerebellar infarcts identify patients with giant cell arteritis.Therapeutic advances in neurological disorders · 2026Article
- Article
- Vessel wall MRI in giant cell arteritis: standardized protocol and scoring approach developed by an international working group.Rheumatology (Oxford, England) · 2025Review
- Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.Immunity, inflammation and disease · 2025Review
- Giant Cell Arteritis with Intracranial and Extracranial Aneurysms: A Case Report and Brief Review of the Literature.Cureus · 2024Article
- Giant cell vasculitis as a mimicker of cerebral amyloid angiopathy related inflammatory disease.Acta neurologica Belgica · 2024Article
- Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis.RMD open · 2023Article
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Giant cell arteritis with severe intracranial involvement diagnosed and treated early.Surgical neurology international · 2023Article
- Giant cell arteritis of the middle cerebral artery.BMJ case reports · 2022Article
- Carotid Artery Stenosis and Ischemic Strokes in Patients with Giant Cell Arteritis: A Characteristic Pattern-Literature Review and Case Report.TH open : companion journal to thrombosis and haemostasis · 2022Review
- Giant cell arteritis with simultaneous onset of multiple intracranial vascular occlusions: A case report.Surgical neurology international · 2022Article
- Intracranial Giant Cell Arteritis Progressing despite Treatment with High Doses of Corticosteroids: Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGiant cell arteritis (GCA) is a large-vessel vasculitis that primarily affects the aorta and its branches. Extracranial branches of the carotid artery are frequently affected; however, intracranial involvement in GCA is rare.
methodsA retrospective medical record review was performed to identify all patients with intracranial GCA (IC-GCA) from January 1996 through May 2018.
resultsNine patients with IC-GCA were included (78% male; mean age, 72.1 years [SD: 7.9]). All patients met ACR criteria for GCA. The median time from onset of GCA to intracranial involvement was 0.6 months (interquartile range: 0.1-5.1). All patients had neurologic symptoms, 89% had an ischemic cerebrovascular event. Transient or permanent vision loss was frequent (56% of patients). IC-GCA was diagnosed by cranial imaging in all nine patients. Intracranial vasculitis most commonly affected the internal carotid artery (100%), followed by the vertebral artery (67%), posterior cerebral artery (67%), middle cerebral artery (44%), anterior cerebral artery (33%), and posterior inferior cerebral artery (11%). Intracranial vessel stenosis was present in 89%, occlusion in 33%, wall thickening in 33%, and dilation in 11%. All patients received glucocorticoids. Additional therapeutic agents included cyclophosphamide (67%) and tocilizumab (22%). Despite treatment, five patients had rapid deterioration and mortality. Comparing IC-GCA patient survival to the expected rates from the US population, the standardized mortality ratio (95% CI) for IC-GCA was 58.1 (18.9-135.6).
conclusionAlthough rare, IC-GCA is associated with significant morbidity and mortality. It occurs predominantly in men and presents with ischemic cerebrovascular events. Current treatment strategies appear to be of limited efficacy for IC-GCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.